Why Site Payments Are Broken (And Why It Matters)

The economics of clinical trials have shifted in ways that make manual site payment processes increasingly untenable. Trial complexity has climbed steadily for two decades, with Tufts CSDD estimating that nearly 60% of protocols require amendments and site activation costs averaging roughly $1,500 per site per month.6 At the same time, sites have taken on more of the administrative load, with more than 25% additional burden in patient education and technology training from decentralized trial elements alone.6 Payment operations have not modernized in step, and the gap is becoming visible in the form of site attrition, protocol delays, and a growing chorus of site-network complaints about sponsor payment behavior.

23% of clinical research sites experience payment delays of 90 days or longer1
84% of sites want to be paid within 30 days or less3
40% of sites drop out of FDA-regulated trials, with payment friction among the top drivers3

The mechanics of the problem are well documented. Sponsor payment terms are typically quarterly, meaning a site may not see funds for work completed in month one until month five or six, while its payroll, rent, and utility obligations continue on standard commercial cycles.3 When payments do arrive, they frequently arrive without clear allocation to specific patients, visits, or procedures, forcing site finance teams to reconcile against internal tracking spreadsheets that may or may not match sponsor budgets.1 The Society for Clinical Research Sites has spent years building resources like the Site Invoiceables Toolkit to help sites capture unfunded activities that erode margins, but those resources only work when sponsors and CROs meet them halfway with transparent, predictable payment structures.7

The Real Cost to Sponsors

The temptation for sponsor finance teams is to view payment delays as a site problem rather than a sponsor problem. That framing was defensible when investigator retention was strong. It is no longer defensible in 2026. Site turnover slows enrollment, protocol-level financial reconciliation costs escalate as manual invoicing volumes climb, and site-facing reputations become a real factor in feasibility responses. Sponsors that consistently pay late or opaquely find fewer high-performing sites accepting their trials, which lengthens study timelines in ways that dwarf whatever working-capital benefit slow payments were supposed to deliver.2

The internal cost is also higher than most finance leaders realize. Manual accounts payable processes for clinical trial site payments typically require dedicated staff to log invoices, reconcile against milestones, chase down missing documentation, and process payments in the study currency. A single global Phase III study in twelve countries may involve twelve currencies, twelve tax regimes, and hundreds of invoice line items per site per quarter.8 When banks and FX conversions consume 3-5% of each payment on top of the labor cost, the fully loaded cost of manual site payment operations approaches the cost of the automation platforms designed to replace them.8

The Signal from CROs and Site Networks

An underappreciated dynamic in 2026 is that the pressure to modernize is no longer coming primarily from sponsors. Large CROs are beginning to mandate automated payments in new contracts because the manual approach damages their site relationships as much as it damages the sponsor’s, and site networks are becoming increasingly explicit about which sponsors they will and will not work with.18 Feasibility responses now routinely include questions about payment timing, portal availability, and dispute resolution channels. A sponsor that cannot answer those questions credibly is competing for sites at a structural disadvantage regardless of therapeutic-area strength or study design quality.

The other signal comes from regulatory inspectors. EMA and FDA reviewers increasingly examine participant and site payment records to verify transparency and compliance, and inspectors have begun issuing findings when payment logs are missing, inconsistent, or unable to be traced back to specific study events.8 Automated platforms produce this audit trail as a by-product of their normal operation. Manual processes require someone to reconstruct it after the fact, which is expensive when it is possible at all.

The strategic question. Sponsors are not really choosing between manual and automated payments. They are choosing between accepting the current cost structure and reallocating that budget toward a platform that also compresses cycle time, improves site relationships, and produces the audit trail regulators increasingly expect.

The 2026 Vendor Landscape

The site-payments market has consolidated and matured meaningfully in the past 18 months. The most significant move was the January 2025 announcement that Suvoda and Greenphire would merge, a transaction that closed in April 2025 and created a combined company supporting more than 1,800 trials across 95 countries.4 Greenphire continues as a product brand under the Suvoda corporate umbrella, and its eClinicalGPS site payment product remains one of the two most widely deployed platforms in the industry.9

IQVIA’s September 2025 launch of its Clinical Trial Financial Suite (CTFS) marked the second major structural shift. CTFS Site Payments, the first module on the platform, ingests clinical trial agreements from multiple formats using AI agents, extracts key financial terms, automates invoice and payment workflows, and routes payment files into sponsor systems. IQVIA is projecting up to a 50% reduction in processing time and 30-day payment cycles with the platform, with general commercial availability scheduled for Q1 2026 following a Q4 2025 sandbox release.5 Medidata Site Payments, Advarra’s Clinical Conductor and OnCore payment modules, WCG’s site enablement portfolio, and Sitero’s Mentor Site Payments round out the credible platform set that sponsors should include in any 2026 evaluation.101112

How the Major Platforms Differ

Platform Notable Strengths Best-Fit Scenario
Greenphire eClinicalGPS (Suvoda) Broadest deployment base, mature EDC-triggered payments, deep site portal, global tax and FX handling Sponsors and CROs with existing Greenphire footprints or high global-trial density; strong site-facing legacy relationships
IQVIA CTFS Site Payments Agentic AI for CTA ingestion, integrated with IQVIA’s broader clinical operations stack, real-time dashboards Sponsors already leveraging IQVIA CRO or technology services; those wanting to consolidate financial and operational data
Medidata Site Payments Native integration with Rave EDC, Grants Manager with Dynamic FMV, managed services option Rave-based sponsors seeking end-to-end budget-to-payment on a single platform; teams with limited in-house payment operations
Advarra (Clinical Conductor / OnCore) Site-first design, strong participant payment integration, CTMS-embedded workflows Sponsors working heavily with Advarra-CTMS academic and network sites; strong sponsor-site data-sharing needs
WCG Site Network + Payments Integrated feasibility, budget negotiation, and payment execution across 470+ site network Sponsors wanting a bundled site-enablement model rather than a standalone payments platform
Sitero Mentor Site Payments Unified CTMS/EDC/payments stack, strong integration with ERP systems, 60+ client base13 Mid-sized sponsors and CROs seeking a single-vendor eClinical suite rather than best-of-breed integration

The Sakara Digital perspective. The platforms are converging faster than sponsors realize. Every major vendor now claims EDC-triggered payments, real-time dashboards, and global currency support. The differentiators that matter in a pilot are the ones that show up under load: how the platform handles amendment cascades, how the site portal behaves during a payment dispute, and how cleanly payment files flow into your existing ERP. Vendor demos will not tell you these things. A structured pilot will.

A Framework for Automated Site Payments

Before selecting a platform, sponsors need a clear internal picture of what “automated site payments” actually means for their operating model. The framework below organizes the capability into five interlocking components. A pilot should evaluate each of them explicitly, and a production deployment should implement all of them together.

Component 1

Milestone Triggers

Payment events are generated automatically when defined operational milestones occur in CTMS, EDC, or eTMF: site activation, patient consent, completed study visits, resolved queries, closeout. No human data entry between milestone and payment calculation.14

Component 2

Invoice-Less Flows

Sites do not raise invoices for scheduled visit payments. The platform generates a system-of-record payment obligation from the trigger event and sends the site a payment notification with full visit-level detail. Invoices remain only for genuine ad-hoc costs.9

Component 3

Budget-Adherent Tracking

Every triggered payment is validated in real time against the executed CTA budget, applicable amendments, and FMV thresholds. Deviations are flagged for review rather than silently paid or silently rejected, and the audit trail is retained for finance and regulators.15

Component 4

Cross-Currency Handling

Payments are executed in each site’s local currency using negotiated FX rates, with automatic tax withholding and country-specific invoicing where required. More than 70 countries maintain unique reimbursement or tax rules that the platform must handle without manual intervention.8

Component 5

Systems Integration

Payment files flow into the sponsor’s ERP (SAP, Oracle, Workday) for execution. Milestone data flows in from CTMS and EDC. Document evidence flows through to eTMF. The site portal is the sole source of truth for the site’s view of what has been paid and what is pending.16

Cross-Cutting

Governance and Audit Trail

Every triggered payment, budget check, amendment adjustment, and manual override generates an immutable audit record. Regulators and internal auditors can trace any payment from ERP entry back to the CTMS event that generated it, in a single query.8

Why Each Component Matters

Milestone triggers are the single most important shift. Manual site payment processes are triggered by invoices, which means the site does administrative work first and then waits for reconciliation. Milestone-triggered payments invert the pattern: the operational event is the primary record, and payment follows automatically. This is the change that produces the reported 90% reduction in site invoicing effort and 24-hour post-approval payment delivery cited by leading platforms.9

Invoice-less flows are the operational manifestation of milestone triggering, but they need explicit design. Sites still need clear payment remittance detail, a way to raise ad-hoc invoices for unscheduled activities, and a formal channel for disputes. The platforms differ meaningfully in how they handle each of these; a pilot should test all three.

Budget-adherent tracking is where automation becomes materially safer than manual processing. A human AP clerk cannot realistically catch every case where a triggered payment exceeds the CTA’s per-visit budget after an amendment. A rules engine can, and the resulting alerts are one of the highest-value outputs of the platform for the sponsor’s finance and clinical operations teams.

Cross-currency handling is often deprioritized in pilots because the pilot is scoped to one country. This is a mistake. If the platform is going to be scaled to global trials, the pilot needs to include at least one non-USD site so that the FX, tax, and country-specific invoicing behaviors are actually stress-tested.8

Systems integration is where most pilots quietly fail. Vendor demos show clean bidirectional flows with CTMS, EDC, and ERP. Real deployments involve legacy versions, non-standard field mappings, and edge cases the vendor’s professional services team has to work through. The pilot must exercise the full round trip: CTMS event to payment file to ERP entry to remittance to site.

Pilot Design: A 90-Day Structured Evaluation

The right pilot is small enough to control and large enough to be representative. The design that consistently produces useful decisions is a single therapeutic area, three to five sites, one representative study, a 90-day evaluation window, and a pre-committed decision framework. Anything larger becomes a de facto production deployment. Anything smaller cannot exercise the edge cases that determine whether the platform will scale.

1

Week 0-2: Charter and stakeholder alignment

Finalize the pilot charter, secure executive sponsorship in clinical operations and finance, agree on the decision criteria before the pilot begins, and confirm the site cohort. Send the participating sites a formal pilot-participation notice with realistic expectations and a named sponsor-side point of contact.

2

Week 2-4: Configuration and integration

Configure the platform for the pilot study: budget import, milestone-to-payment mapping, amendment scenarios, tax and FX settings for the participating countries. Establish the CTMS-to-platform-to-ERP integration in a test environment and run three end-to-end synthetic scenarios before touching real payments.

3

Week 4-8: Live processing with parallel run

Run the platform in parallel with the existing manual process for four weeks. Every payment goes through both flows, with the manual flow remaining the system of record. This period exists to catch configuration errors, mapping mistakes, and edge cases without exposing sites to disruption.

4

Week 8-11: Platform as primary flow

Cut over to the platform as the primary payment path. Retain the manual flow as backup and reconciliation. Deliberately introduce two or three amendment or dispute scenarios if none occur naturally, so that the platform’s exception handling is tested. Collect the metrics that will drive the decision.

5

Week 11-13: Evaluation and decision

Convene the steering committee, walk through the pre-committed decision framework against the collected metrics, interview site coordinators from the participating sites, and produce the scale-or-stop recommendation. Communicate the outcome to the sites regardless of the decision.

The Site Cohort

The site cohort choice matters more than most pilot leads treat it. A useful pilot includes at least one site of each of the following types:

  • A high-volume site with mature study management capacity, so the platform’s happy path is exercised at realistic volume.
  • A smaller academic or independent site with limited finance headcount, so the platform’s site-portal usability is tested by staff who cannot compensate for a difficult interface.
  • An international site, ideally in a non-USD country with meaningful tax withholding requirements, so the FX and country-specific invoicing behavior is tested rather than assumed.
  • A site with a known payment complaint history, if one exists in the sponsor’s portfolio, so that the change is evaluated in the context of an existing problem rather than a greenfield.

The Study Choice

The pilot study should be active, mid-enrollment, and complex enough to have meaningful visit variety. A closeout-phase study will not generate enough payment events. A start-up-phase study will not generate enough of the recurring visit payments that the platform is designed to automate. A study with a single visit type and no amendments will not exercise the budget-adherent tracking or amendment cascade behaviors that determine production readiness. Choose a study with at least three visit types, at least one executed amendment, and roughly half of enrollment completed.

What “Parallel Run” Actually Requires

The parallel-run phase in weeks 4-8 is deceptively hard to design well. In principle, every payment goes through both the platform and the manual process, with the manual process remaining authoritative. In practice, the parallel run only produces useful learning if the discrepancies between the two flows are surfaced, analyzed, and resolved rather than quietly ignored. Sponsors that treat the parallel run as a compliance exercise learn nothing from it. Sponsors that treat it as an active reconciliation, with a weekly review of every discrepancy and a documented root cause, uncover the configuration errors and mapping mistakes that would otherwise surface only in production. The parallel run is also the point at which the AP team’s ownership of the platform is either established or lost. If the AP team spends the four weeks watching from the sidelines, the pilot has already failed regardless of the metrics; if the AP team is running both flows and comparing them, the operational muscle is being built at exactly the right pace.

Common Pilot Failure Modes and How to Avoid Them

Roughly 80% of healthcare technology pilots fail to scale beyond the pilot phase, and clinical operations pilots are no exception.17 The failure modes are consistent enough to name, which is the first step toward avoiding them.

The seven failure modes that quietly kill site-payment pilots. Each is fixable if it is anticipated. Most are unfixable once they have taken root, because the political capital to reset the pilot rarely exists after month two.

1. Technical success without operational buy-in.

The pilot processes payments correctly, but the AP team never fully engages, treats the platform as a parallel toy system, and continues to run the manual process as the real system of record.17 The pilot report reads well and the change never scales. The fix is to name the AP lead as a pilot co-owner from day one and to build the evaluation criteria with them.

2. Site cohort too homogeneous.

The pilot is run with three friendly, high-performing sites who cooperate with anything the sponsor puts in front of them. The report shows the platform works perfectly. The production rollout hits a difficult site in month three and the platform’s edge-case handling was never tested. The fix is the cohort composition described earlier.

3. No pre-committed decision framework.

The pilot succeeds, but the criteria for “success” were never defined, and the steering committee spends its evaluation meeting debating what “success” should mean. Political dynamics take over, the decision drifts, and the pilot enters an indefinite extension. The fix is a written decision framework signed by clinical operations, finance, and IT leadership before the pilot begins.

4. Systems integration deferred to production.

The pilot uses spreadsheet imports and manual payment file transfers to accelerate the timeline. The platform’s actual integration behavior with CTMS, EDC, and ERP is never tested in the pilot. Production rollout uncovers integration friction that would have killed the pilot if it had been known. The fix is to require full round-trip integration testing in the pilot, even if it lengthens the setup phase.

5. Change management underinvested.

Training alone does not drive adoption in clinical environments with competing stakeholder priorities.17 If sites and internal AP staff are not walked through the workflow change, given a defined support channel, and given time to build competence, they will revert to familiar workarounds. The fix is to budget change management effort at roughly one-third of the technical implementation effort, not as an afterthought.

6. Vendor over-promising on demos.

The demo environment shows agentic AI parsing every CTA cleanly, real-time dashboards updating instantly, and no exception cases. The production environment is messier. Sponsors that treat the demo as the specification are systematically disappointed. The fix is to require the vendor to run at least one of the sponsor’s real CTAs through the platform during procurement, ideally an amended one, and to observe the result.

7. Absent scale-up plan.

The pilot succeeds and the organization has no defined path from “one study, five sites” to “portfolio-wide deployment.” The pilot report gets circulated, everyone agrees the platform is promising, and the effort dies from inertia. The fix is to draft the scale-up plan during the pilot, not after. If the pilot succeeds, execution begins the following month.

What separates pilots that scale. Every pilot that reaches production shares three characteristics: an executive sponsor with real authority to decide, a written decision framework signed before the pilot begins, and a designated production owner named on day one. Missing any of these makes scaling a coin flip regardless of how well the platform performs.

Pilot Charter Template, Metrics, and Stakeholders

A pilot charter is not a project plan. It is the artifact that keeps the pilot honest when politics, timelines, and priorities shift during the 90 days. The template below is what a defensible site-payment pilot charter contains.

Pilot Charter Template

Executive Sponsor and Governance

Name the executive sponsor (typically SVP Clinical Operations or CFO delegate), the pilot lead (a director-level clinical operations or finance leader), the steering committee (clinical operations, finance/AP, IT/systems integration, procurement, quality/audit), and the decision authority. Meeting cadence is weekly during weeks 0-4 and biweekly thereafter.

Scope

State the therapeutic area, study, site cohort, geographies, and platform under evaluation. Explicitly list what is out of scope: participant payments unless integrated, other studies at the same sites, other studies in the same therapeutic area.

Objectives

Three to five specific, testable objectives. For example: “Reduce mean site payment cycle time from current baseline to 30 days or fewer for pilot-scope payments.” “Reduce site-initiated payment inquiries by at least 50% relative to baseline.” “Achieve full round-trip integration between CTMS, platform, and ERP without manual data movement.”

Success Metrics

Quantitative metrics with pre-committed thresholds, qualitative metrics with a defined collection method, and the specific decision rule. Missing this section is what turns pilots into indefinite extensions.

Metric Baseline Target Collection Method
Mean site payment cycle time (milestone to receipt) 60-90 days (typical) ≤ 30 days Platform timestamps + ERP payment execution date
Site-initiated payment inquiries per site per month Baseline pull from AP inbox ≥ 50% reduction Ticketing system + AP inbox audit
AP staff hours per payment cycle Time-tracking baseline ≥ 40% reduction AP time-tracking during pilot
Payment exception rate (flagged for review) Not measured in manual process ≤ 5% of triggered payments Platform exception log
Site satisfaction (structured interview) Sponsor site-survey benchmark Positive delta on 5 defined dimensions Structured interview at week 11
Full round-trip integration achieved Not applicable Yes, without manual data movement IT sign-off in week 6

Decision Rule

The pre-committed rule for what the steering committee will do at week 13. Example: “The pilot proceeds to a portfolio scale-up plan if at least four of six success metrics are met and no critical integration or audit issues are outstanding. If three or fewer metrics are met, the pilot is closed and the organization returns to the vendor evaluation phase. If exactly three or four metrics are met and the missed metrics have identifiable, addressable causes, the steering committee may authorize a 45-day pilot extension with revised criteria.”

Risks and Mitigations

Identify the top five risks specific to this pilot, with named mitigation owners. Do not use generic risk boilerplate. The site-payment pilot risks that typically matter are: site refusal to participate, integration slippage, executed amendment during pilot, key AP staff turnover, and vendor resource availability during setup.

Stakeholder Engagement Plan

Every stakeholder group needs a defined message, a defined channel, and a defined cadence. The plan below is the minimum viable structure.

Stakeholder Key Message Channel Cadence
Executive sponsor Pilot health, key decisions, escalations Written status + 30-min steering Biweekly
Site coordinators (pilot sites) What is changing, what to expect, who to call Kick-off webinar + named liaison Weekly office hours
Site finance leads (pilot sites) Payment schedule, remittance detail, dispute path Written FAQ + direct email As-needed
Internal AP team Workflow change, ownership boundaries, escalations Working sessions + dedicated Slack/Teams Twice weekly
Clinical operations study team Milestone-trigger definitions, exception handling Working sessions Weekly during setup, biweekly thereafter
IT and systems integration Integration scope, testing plan, cutover criteria Working sessions + Jira/ADO Weekly
Procurement and legal MSA/DPA status, data handling, scope for scale-up contract Written updates Monthly
Quality and audit Audit trail, GxP considerations, inspection readiness Working sessions At weeks 2, 6, 11

From Pilot to Production: The Scaling Decision

The scaling decision is the moment the organization discovers whether the pilot was set up to succeed as a real change or as a demonstration. A well-structured pilot produces a defensible recommendation at week 13. A well-structured organization has already drafted the scaling plan by week 8 so that execution can begin in the month after the decision.

The Scaling Plan

The scaling plan should answer four questions. First, what is the phased rollout sequence, and what defines a phase? A reasonable pattern is: pilot therapeutic area first (weeks 14-26), second therapeutic area or region (weeks 26-40), remaining active trials (weeks 40-65), and legacy trials at closeout as convenience allows. Second, who owns production operations? The pilot lead is rarely the right permanent owner; a named business owner in clinical operations and a named technical owner in IT should be identified before rollout begins. Third, how are additional sites and studies onboarded? A repeatable onboarding playbook, drafted from the pilot experience, is the artifact that determines whether scaling proceeds at pace or stalls. Fourth, what is the sunset plan for the manual process? Running two systems indefinitely is a common failure mode; the plan should state when the manual process is retired and what triggers the retirement.

The Scaling Metrics

Scale-up should be measured on a different set of metrics than the pilot. The pilot measured whether the platform works. Scale-up measures whether the operating model is sound: onboarding cycle time per new study, per-study support burden on the central team, exception rate trend, and site satisfaction across the growing cohort. A well-run scale-up program should see these metrics improve with volume as the operating model matures, not degrade.

One final scaling consideration deserves explicit attention: the contract with the platform vendor should not be finalized until the pilot has produced its recommendation. Sponsors that sign multi-year enterprise agreements before running the pilot lose the leverage that makes a pilot commercially useful. A well-structured procurement approach uses a pilot-scope contract for the 90-day window, with a pre-negotiated framework agreement that converts to a full enterprise contract if the pilot succeeds against pre-committed criteria. This structure gives the vendor confidence that a successful pilot means real revenue, and it gives the sponsor a defensible exit if the pilot does not meet its threshold.

The Sakara Digital perspective. Sponsors that treat the pilot as procurement usually pick a platform and then spend the next 18 months trying to make it work. Sponsors that treat the pilot as an operational transformation usually pick the same platform and reach production in half the time. The difference is not the platform. It is whether the organization used the 90-day pilot window to build the operating muscle the platform requires. If the pilot succeeds only because a small group of talented people held it together by force of will, the platform will not scale, and no vendor selection can fix that.

Conclusion

Site payment automation has moved from a nice-to-have to an operational imperative. The industry data is unambiguous: sites are demanding 30-day payment cycles, vendors are delivering the technology to enable them, and sponsors that hold onto quarterly cycles will pay for it in feasibility responses, protocol timelines, and site retention. The 2026 vendor landscape offers credible platforms across every major CRO and technology footprint, which means the sponsor’s problem is no longer whether to automate but how to pilot the transition without creating new failure modes.

A structured 90-day pilot on a single therapeutic area with three to five sites, tied to milestone triggers, invoice-less flows, budget-adherent tracking, cross-currency handling, and full systems integration, is the pragmatic path. The pilot must be governed by a signed charter with pre-committed success metrics and a pre-committed decision rule. It must include the operational stakeholders who will run the platform in production. It must anticipate the seven failure modes that quietly kill most technology pilots. And it must produce a scaling plan drafted during the pilot rather than after it.

Sakara Digital works with pharma and biotech organizations building this kind of operational change into their clinical operations and finance functions. If you are exploring a site-payment automation pilot and want an independent perspective on where to start, who to include, and what to test before you sign a scale-up contract, we are happy to have that conversation.